Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 743 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Cancer Stage I Clear all
Completed Phase 1 Interventional

Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer

NCT00002519
View directory record Official record
Conditions
Lung Cancer
Interventions
chemotherapy, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 15, 2026, 11:58 PM EDT
Terminated Phase 1 Interventional

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

NCT06599502
View directory record Official record
Conditions
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions
AZD0022, Cetuximab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Duarte, California • New York, New York • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

NCT05642195
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Interventions
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
Biological · Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

NCT02422381
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
MK-3475, Gemcitabine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Recruiting Phase 2 Interventional

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

NCT06693336
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Interventions
SMS001
Drug
Lead sponsor
ToLymph Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00589056
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, nelfinavir mesylate, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

NCT00005023
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Not applicable Interventional

Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer

NCT01840150
View directory record Official record
Conditions
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
Interventions
breath test, laboratory biomarker analysis
Procedure · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00280150
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 15, 2026, 11:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT01770418
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Radiation with Concurrent Chemotherapy
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Withdrawn Not applicable Interventional

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

NCT02250378
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions
stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
Radiation · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 15, 2026, 11:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362
View directory record Official record
Conditions
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions
BT8009, Pembrolizumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Results available

Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study

NCT03306992
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Secondary Lung Cancer
Interventions
Personalized Exercise Program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1 Interventional

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

NCT01594398
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions
entinostat, Erlotinib, Exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 15, 2026, 11:58 PM EDT
Active, not recruiting Phase 3 Interventional Results available

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106
View directory record Official record
Conditions
Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions
AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

NCT03110978
View directory record Official record
Conditions
Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma, Neuroendocrine Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Large Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8
Interventions
Nivolumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Conroe, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1 Interventional

Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer

NCT02172846
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Proton beam radiation therapy (PBT), Paclitaxel, Carboplatin
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 15, 2026, 11:58 PM EDT
Active, not recruiting No phase listed Observational

Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations

NCT07581379
View directory record Official record
Conditions
Lung Neoplasms, Second Primary Lung Cancer (SPLC), Non-Small Cell Lung Cancer (NSCLC), Stage I-IIIA, Lung Cancer (Diagnosis)
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
1,826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

NCT00826449
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
Dasatinib, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 15, 2026, 11:58 PM EDT
Terminated No phase listed Observational

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00008216
View directory record Official record
Conditions
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Peripheral Blood Stem Cell Transplantation
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1Phase 2 Interventional

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

NCT00101348
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Colon Cancer, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
erlotinib hydrochloride, cetuximab, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 15, 2026, 11:58 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00023985
View directory record Official record
Conditions
Lung Cancer
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells, conventional surgery
Biological · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 15, 2026, 11:58 PM EDT
Terminated Phase 1 Interventional

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

NCT00689065
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
CALAA-01
Drug
Lead sponsor
Calando Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 15, 2026, 11:58 PM EDT
Recruiting Phase 2 Interventional

Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

NCT07718672
View directory record Official record
Conditions
Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymph Node Biopsy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 11:58 PM EDT